Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

July 27, 2022

Greenwich biotech asks FDA to test psilocybin as treatment for alcohol use disorder

Greenwich-based bioscience company B.More Inc. submitted an investigational new drug (IND) application to the FDA for the use of synthetic psilocybin in treatment of alcohol use disorder, the company announced this week. 

B.More, a nonprofit biopharma firm, is seeking to launch a Phase 2b trial slated to start in early 2023, to be led by Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine. 

With a planned 226 participants, the study would be the second largest psychedelics clinical trial ever conducted if approved, according to B.More. It would assess the 24-week efficacy and safety of synthetic psilocybin (SYNP-101) in treating moderate to severe alcohol use disorder.

CEO Carey Turnbull said, “B.More’s psilocybin [alcohol use disorder] program IND application is a major step forward in our mission to develop psychedelic medicines for individuals struggling with alcohol use disorder.”

Carey and Claudia Turnbull founded B.More in 2017 and named the company for Claudia Turnbull’s brother, who died of a drug overdose. 

“B.More is focused on the development and commercialization of psychedelic medicines that offer the potential to dramatically improve the lives of those for whom current treatment options have not proved effective,” according to a company statement. 

Contact Liese Klein at

Sign up for Enews


Order a PDF